|
1
|
Yan JF, Qin WP, Xiao BC, Wan QQ, Tay FR,
Niu LN and Jiao K: Pathological calcification in osteoarthritis: An
outcome or a disease initiator? Biol Rev Camb Philos Soc.
95:960–985. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Taylor AM: Metabolic and endocrine
diseases, cartilage calcification and arthritis. Curr Opin
Rheumatol. 25:198–203. 2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Furukawa K: Pharmacological aspect of
ectopic ossification in spinal ligament tissues. Pharmacol Ther.
118:352–358. 2008.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pike JW and Christakos S: Biology and
mechanisms of action of the vitamin D hormone. Endocrinol Metab
Clin North Am. 46:815–843. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Arnold A, Dennison E, Kovacs CS, Mannstadt
M, Rizzoli R, Brandi ML, Clarke B and Thakker RV: Hormonal
regulation of biomineralization. Nat Rev Endocrinol. 17:261–275.
2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Nakamichi Y, Udagawa N, Suda T and
Takahashi N: Mechanisms involved in bone resorption regulated by
vitamin D. J Steroid Biochem Mol Biol. 177:70–76. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ao T, Kikuta J and Ishii M: The effects of
vitamin D on immune system and inflammatory diseases. Biomolecules.
11(1624)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Charoenngam N: Vitamin D and rheumatic
diseases: A review of clinical evidence. Int J Mol Sci.
22(10659)2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Harrison SR, Li D, Jeffery LE, Raza K and
Hewison M: Vitamin D, autoimmune disease and rheumatoid arthritis.
Calcif Tissue Int. 106:58–75. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Welldon KJ, Findlay DM, Evdokiou A, Ormsby
RT and Atkins GJ: Calcium induces pro-anabolic effects on human
primary osteoblasts associated with acquisition of mature osteocyte
markers. Mol Cell Endocrinol. 376:85–92. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Drewnowski A and Shultz JM: Impact of
aging on eating behaviors, food choices, nutrition, and health
status. J Nutr Health Aging. 5:75–79. 2001.PubMed/NCBI
|
|
12
|
Takahashi N, Akatsu T, Udagawa N, Sasaki
T, Yamaguchi A, Moseley JM, Martin TJ and Suda T: Osteoblastic
cells are involved in osteoclast formation. Endocrinology.
123:2600–2602. 1988.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Li J, Sarosi I, Yan XQ, Morony S,
Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, et al:
RANK is the intrinsic hematopoietic cell surface receptor that
controls osteoclastogenesis and regulation of bone mass and calcium
metabolism. Proc Natl Acad Sci USA. 97:1566–1571. 2000.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Boyle WJ, Simonet WS and Lacey DL:
Osteoclast differentiation and activation. Nature. 423:337–342.
2003.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mori T, Horibe K, Koide M, Uehara S,
Yamamoto Y, Kato S, Yasuda H, Takahashi N, Udagawa N and Nakamichi
Y: The vitamin D receptor in osteoblast-lineage cells is essential
for the proresorptive activity of 1α,25(OH)2D3 in vivo.
Endocrinology. 161(bqaa178)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sun J, Sun B, Wang W, Han X, Liu H, Du J,
Feng W, Liu B, Amizuka N and Li M: Histochemical examination of the
effects of high-dose 1,25(OH)2D3 on bone remodeling in young
growing rats. J Mol Histol. 47:389–399. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Han X, Zhu N, Wang Y and Cheng G:
1,25(OH)2D3 inhibits osteogenic differentiation through activating
β-catenin signaling via downregulating bone morphogenetic protein
2. Mol Med Rep. 22:5023–5032. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yamaguchi M and Weitzmann MN: High dose
1,25(OH)2D3 inhibits osteoblast mineralization in vitro. Int
J Mol Med. 29:934–938. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yang D, Turner AG, Wijenayaka AR, Anderson
PH, Morris HA and Atkins GJ: 1,25-Dihydroxyvitamin D3 and
extracellular calcium promote mineral deposition via NPP1 activity
in a mature osteoblast cell line MLO-A5. Mol Cell Endocrinol.
412:140–147. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Misgar RA, Sahu D, Bhat MH, Wani AI and
Bashir MI: Vitamin D toxicity: A prospective study from a tertiary
care centre in Kashmir Valley. Indian J Endocrinol Metab.
23:363–366. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Abhishek A and Doherty M: Pathophysiology
of articular chondrocalcinosis-role of ANKH. Nat Rev Rheumatol.
7:96–104. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Heneghan C and Mahtani KR: Vitamin D does
not prevent fractures and falls. BMJ Evid Based Med. 24:147–148.
2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chiodini I and Gennari L: Falls, fractures
and vitamin D: A never-ending story? Nat Rev Rheumatol. 15:6–8.
2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gallagher JC: Vitamin D and bone density,
fractures, and falls: The end of the story? Lancet Diabetes
Endocrinol. 6:834–835. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Bolland MJ and Grey A: A case study of
discordant overlapping meta-analyses: Vitamin D supplements and
fracture. PLoS One. 9(e115934)2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Burt LA, Billington EO, Rose MS, Kremer R,
Hanley DA and Boyd SK: Adverse effects of high-dose vitamin D
supplementation on volumetric bone density are greater in females
than males. J Bone Miner Res. 35:2404–2414. 2020.PubMed/NCBI View Article : Google Scholar
|
